Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01946789 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01946789 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 26 participants.
The verdict
NCT01946789, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head and neck cancer
Interventions
- BIOLOGICAL ALT-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2014-05 |
| Est. Completion | 2017-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01946789
The ClinicalTrials.gov registry entry for NCT01946789 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALT-803 is the first listed.
NCT01946789 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01946789 about?
NCT01946789 is a clinical study titled "A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors". The proposed clinical trial is a phase I, open-label, multi-center, dose-escalation study of ALT-803 in patients with surgically incurable advanced solid tumors: melanoma, renal cell, non-small cell lung and squamous cell head and neck cancer
What is the current status of trial NCT01946789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2014-05. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01946789?
The interventions under investigation include: ALT-803 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01946789?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.